If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
214
results.
Updated on
16/02/2026 [06:51:00]
Results 25 to 50 of 214
Absstract of: WO2026033411A1
The present invention discloses a formulation of bioactive liposomal gummies and a process of preparation thereof. The formulation comprises a bioactive component, an encapsulating agent, a sweetening agent, a flavoring agent, a gelling agent, an acidity regulator, a coloring agent, a bulking agent, a texturing agent, a thickening agent, a cross-linking polymer and water. The invention discloses a method of preparation of bioactive liposome using nano-milling process subsequently high-pressure homogenization, followed by a spray drying process. The process results in formulating dried bioactive liposomal gummies that exhibit increased stability and bioavailability of the liposomes making it a suitable for drug delivery system for wide range of bioactive agents. The bioactive liposomal gummies exhibit pH and temperature stability along with being palatable.
Absstract of: AU2024308529A1
Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.
Absstract of: WO2026034613A1
The present invention provides an adjuvant comprising a B-type CpG oligodeoxynucleotide (CpG ODN), a modification thereof, or a complex thereof, to be administered together with an mRNA vaccine in which mRNA is encapsulated in particles. The adjuvant contains the B-type CpG ODN that is present independently of the particles that encapsulate mRNA. This adjuvant can enhance antigen-specific cytotoxic T cell (CTL) induction by mRNA vaccines.
Absstract of: WO2026033240A1
The invention relates to compounds of general formula (I), where X1, X2, X3 and y are defined in the description. The invention further relates to a process for the preparation of said compounds, and to the use of said compounds for the preparation of lipid nanoparticles carrying active ingredients. The invention further relates to a pharmaceutical composition comprising a nanoparticle according to the invention, and to the nanoparticle for use in medicine.
Absstract of: WO2026031838A1
The present invention belongs to the field of pharmaceutical formulations. Specifically disclosed are a nanodrug for synergistically removing fibrosis and inhibiting pancreatic cancer metastasis and a preparation method therefor. By means of the self-assembly of a small-molecule prodrug, excipient-related toxicity is avoided, and a high drug loading rate is achieved. By means of hybrid membrane encapsulation, homologous targeting of fibrotic adhesion interstitium and receptor protein-mediated active targeting are achieved. By means of the response of the prodrug molecule to ROS, massive, rapid, and traceless drug release is achieved in the fibrotic adhesion interstitium, removing the self-limiting characteristic of the release of a responsive small-molecule drug. The released drugs Cap and CA can simultaneously inhibit fibrosis signals/proteins, synergistically removing fibrosis. As the removal of fibrosis progresses, Cap and CA released rapidly and tracelessly in pancreatic cancer cells can simultaneously inhibit the metastasis/invasion signaling pathway of pancreatic cancer cells, synergistically inhibiting metastasis. The dynamic synergy between the process of removing fibrosis and the process of inhibiting metastasis provides a new approach for removing fibrosis in the treatment of pancreatic cancer.
Absstract of: WO2026030816A1
Provided is a lipid nanoparticle comprising capped mRNA bearing one or more ribose modifications, and 20 to 70 mol % of a neutral lipid, an ionizable lipid; and a sterol and optionally a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in extrahepatic protein expression of the mRNA in vivo, as measured in one or more extrahepatic organs or tissues. In some examples, the mRNA comprises a 5' cap having an N7-methylated guanosine at a position 0, and a nucleoside at a position 1 linked to the N7-methylated guanosine by a 5' to 5' bridge, wherein the N7-methylated guanosine has a modification at a 3' carbon of its ribose and/or the nucleoside at the position 1 has a modification at a 2' carbon of its ribose.
Absstract of: WO2026035909A1
This disclosure relates to split-formulated influenza vaccines and methods of immunizing a subject against influenza using the same.
Absstract of: WO2026035680A1
The present disclosure provides lipid nanoparticle compositions and methods of use. Among other things the present disclosure provides lipid nanoparticle compositions which increased specificity for specific cells or tissues. The present disclosure provides methods of use of the disclosed lipid nanoparticles.
Absstract of: WO2026035659A1
The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.
Absstract of: WO2026033348A1
The invention relates to a process for the preparation of a composition comprising an oligosaccharide or a polysaccharide encapsulated in lipid nanoparticles, the process comprising the following steps: preparing a first solution of a lipid portion comprising a phospholipid, a neutral lipid, and a lipid sterol; preparing a second solution comprising a poly- or oligosaccharide; preparing a third solution containing a buffer; mixing the first and second solutions using a microfluidic system to obtain lipid nanoparticles encapsulating the oligosaccharide or the polysaccharide; combining the third solution with the first and second solutions. The invention also relates to a composition comprising lipid nanoparticles obtainable by the above-defined process, said composition comprising a lipid portion comprising a phospholipid, a neutral lipid compound in which a lipid chain is bound to a glycol group, and a lipid sterol; a buffer; and an oligosaccharide or polysaccharide.
Absstract of: WO2026033498A1
Disclosed herein are methods of increasing the potency of saRNA encapsulated lipid nanoparticles (LNPs) through a novel and surprisingly superior LNP manufacturing technique. The method disclosed herein overcomes technical difficulties and high costs associated with previous LNP manufacturing techniques. The methods disclosed herein, therefore, greatly improve the industrial production of LNPs in unexpected ways thereby providing more potent and less expensive LNPs for nucleic acid delivery.
Absstract of: WO2026033123A1
The present invention provides methods of encapsulating messenger RNA in lipid nanoparticles without the use of flammable solvents, and compositions produced by these methods, for mRNA delivery in therapeutic use. In particular, the present invention provides a process of encapsulating messenger RNA in lipid nanoparticles comprising a step of mixing (a) an mRNA solution comprising one or more mRNAs with (b) a lipid solution comprising one or more cationic lipids, one or more non-cationic lipids, one or more PEG-modified lipids, and a solvent, wherein the solvent comprises diethylene glycol monoethyl ether or tert-amyl alcohol, thereby forming mRNA encapsulated within the LNPs.
Absstract of: WO2026032777A1
The present invention relates to a method for obtaining nanodispersed systems comprising the steps of: a) mixing a compound C with a fluid A and obtaining a mixture in the form of a solution or dispersion; b) thermostatising the mixture obtained in step a) at a temperature of between -50 ºC and 200 ºC; c) adding a fluid B to the thermostatised mixture until a pressure P between 0 and 300 bar is attained obtaining the mixture AB; wherein molar fraction of fluid B is from 0.01 to 0.8; d) reducing the pressure of the mixture AB obtained in step c) to a pressure lower than or equal to 10 bar, by means of a valve, wherein said valve is heated during depressurization process to a temperature T in the range of 10 ºC to 50 ºC; and e) mixing fluid A with fluid E in which fluid A is miscible and compound C is partially or totally insoluble, controlling the flow rate and the temperature T of fluid A in the range of 10 ºC to 100 ºC.
Absstract of: US20260041785A1
The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.
Absstract of: US20260042732A1
Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for the delivery of nucleic acids to various types of cells, including T-cells and hepatocytes, in vivo, ex vivo and in vitro.
Absstract of: US20260043801A1
A nanoagent for detections and treatments of multiple targets of interest includes multiple types of nanocomposites, each type of nanocomposites comprising at least one nanostructure, each nanostructure having a core and a shell surrounding the core; a respective reporter assembled on the shell of each nanostructure; and a layer of a respective treating agent and a respective targeting agent conjugated to the respective reporter. In use, each type of nanocomposite targets to a respective target of interest according to the respective targeting agent and releases the respective treating agent and the nanostructure therein for therapeutic treatment of the respective target of interest, and the respective target of interest transmits at least one signature responsive to the respective reporter for detection of the respective target of interest.
Absstract of: US20260041783A1
The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and/or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.
Absstract of: US20260041769A1
The invention relates to agents and methods for targeted delivery of nucleic acids to cells. In some embodiments, the nucleic acid payload comprises a nucleic acid encoding an antigen receptor such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). The agents and methods for targeted delivery of a nucleic acid encoding an antigen receptor described herein may be used for generating in vitro/ex vivo or in vivo immune effector cells genetically modified to express an antigen receptor.
Absstract of: US20260041713A1
Disclosed herein are methods of enhancing skin regeneration, promoting wound healing (e.g., wherein the wound is a burn or actinic keratosis), and/or enhancing the topical delivery of active agents, the methods comprising the steps of applying a topical composition, comprising nanodiamond-zinc oxide core-shell particles, to the skin of a subject in need thereof.
Absstract of: US20260041646A1
A thermally responsive nanosphere for binding to biofilms including a gold nanoparticle core functionalized with a polyethylene glycol; an R2ab fusion protein construct including an anchor that is a stable globular domain having a surface accessible cysteine residue, a linker, an S. epidermidis R2ab protein of SEQ ID NO. 1, and an elastin-like polypeptide. The linker may be a protein having SEQ ID NO. 7; and the anchor may be a modified third IgG binding domain from streptococcal protein G (GB3) having SEQ ID NO. 3, a ubiquitin protein having SEQ ID NO. 4, a Pin1 WW domain having SEQ ID NO. 5, and a fibronectin protein domain 3FN3 having SEQ ID NO. 6. A method for treating a biofilm containing S. epidermidis bacteria by binding a plurality of the nanospheres to the biofilm and exposing the biofilm to laser irradiation.
Absstract of: US20260041855A1
An electronic device includes a mouthpiece, a bladder, and a mesh assembly having a mesh material and a piezoelectric material. The mesh material is in contact with a liquid of the bladder. The mouthpiece, the bladder, and the mesh assembly are located in-line along a longitudinal axis of the device between opposite longitudinal ends of the device, with the mesh assembly extending between and separating the mouthpiece and the bladder. A liquid-filled cartridge also is disclosed for use with an electronic device for delivery of a substance into a body through respiration includes a liquid container; and a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device. The liquid includes a plurality of nanoparticles in a nanoemulsion, the nanoparticles including the encapsulation of the substance to be delivered into the body through respiration. The nanoemulsion preferably is produced using a microfluidizing machine.
Absstract of: US20260041764A1
The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.
Absstract of: US20260041759A1
A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and/or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N/mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.
Absstract of: US20260041643A1
The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Nº publicación: US20260041750A1 12/02/2026
Applicant:
UNIV OF CAPE TOWN [ZA]
UNIV OF THE WITWATERSRAND JOHANNESBURG [ZA]
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV [US]
UNIVERSITY OF CAPE TOWN,
UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG,
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Absstract of: US20260041750A1
The present invention relates to polygenic nucleic acid constructs comprising nucleotide sequences encoding Mycobacterium tuberculosis antigens and to mRNA vaccine constructs transcribed or obtained therefrom. Also provided are lipid nanoparticles including the mRNA vaccine constructs and vaccine compositions comprising the constructs described. The constructs, lipid nanoparticles containing them, and vaccine compositions described may be useful in methods for eliciting a protective immune response against Mycobacterium tuberculosis in a subject.
BOPI
Electronic site
